These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 2708186)
1. Comparison of disc-diffusion and plate-incorporation susceptibility testing of gram-negative bacilli to ticarcillin, piperacillin and ticarcillin/clavulanate. Elston RA; Swann RA; Fraise A J Antimicrob Chemother; 1989 Feb; 23(2):285-7. PubMed ID: 2708186 [No Abstract] [Full Text] [Related]
2. In vitro susceptibility of piperacillin v timentin and ticarcillin. Bremner DA N Z Med J; 1987 May; 100(823):299-300. PubMed ID: 3138579 [No Abstract] [Full Text] [Related]
3. Susceptibility of ticarcillin-resistant gram-negative bacilli to different combinations of ticarcillin and clavulanic acid. Verbist L; Verhaegen J J Antimicrob Chemother; 1986 May; 17 Suppl C():7-15. PubMed ID: 3636338 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of gram-negative bacteria and Staphylococcus aureus to combinations of ticarcillin and clavulanic acid. Casey P; Glauser M Eur J Clin Microbiol; 1983 Dec; 2(6):541-7. PubMed ID: 6607834 [TBL] [Abstract][Full Text] [Related]
5. [Activity of ticarcillin combined with different concentrations of clavulanic acid on 137 Gram-negative bacilli resistant to ticarcillin]. Aubert G; Dorche G; Frere A; Raby N; Denis M Pathol Biol (Paris); 1987 May; 35(5):537-41. PubMed ID: 3302858 [TBL] [Abstract][Full Text] [Related]
6. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Knapp CC; Sierra-Madero J; Washington JA Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423 [TBL] [Abstract][Full Text] [Related]
7. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
8. [Effect of a ticarcillin-clavulanic acid (timentin) combination on bacteria resistant to ticarcillin]. Rouhan D; Le Noc P; Robert J Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):461-5. PubMed ID: 3937121 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility testing recommendations for ticarcillin/clavulanic acid in the Stokes' disc diffusion test. Sutherland R J Antimicrob Chemother; 1989 Sep; 24(3):463-4. PubMed ID: 2808198 [No Abstract] [Full Text] [Related]
10. In-vitro activity of ticarcillin with and without clavulanic acid against clinical isolates of gram-positive and gram-negative bacteria. Pulverer G; Peters G; Kunstmann G J Antimicrob Chemother; 1986 May; 17 Suppl C():1-5. PubMed ID: 3636325 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ticarcillin plus clavulanic acid (BRL 28500, 'Timentin') against ticarcillin-resistant gram-negative rods. Chattopadhyay B; Hall I Curr Med Res Opin; 1984; 9(3):157-60. PubMed ID: 6568146 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro susceptibilities of 504 bacteremic isolates to ticarcillin plus clavulanic acid and other antimicrobial agents. Rotstein C; Amsterdam D; Beam T; Gorzynski E Diagn Microbiol Infect Dis; 1989; 12(2):157-63. PubMed ID: 2752713 [TBL] [Abstract][Full Text] [Related]
13. Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa. Manian FA; Alford RH Antimicrob Agents Chemother; 1986 Jul; 30(1):35-8. PubMed ID: 3092732 [TBL] [Abstract][Full Text] [Related]
14. Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid. Fuchs PC; Jones RN; Barry AL J Clin Microbiol; 1989 Nov; 27(11):2475-81. PubMed ID: 2808671 [TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of the combination ticarcillin-clavulanic acid on bacterial isolates in surgery]. Branger C; Kitzis M; Le Mée J Pathol Biol (Paris); 1986 Apr; 34(4):245-8. PubMed ID: 3528998 [TBL] [Abstract][Full Text] [Related]
16. Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid. Fuchs PC; Jones RN; Barry AL; Thornsberry C J Clin Microbiol; 1984 Apr; 19(4):555-7. PubMed ID: 6715524 [TBL] [Abstract][Full Text] [Related]
17. [Comparative activity of ticarcillin-clavulanic acid and various beta-lactams against Pseudomonas maltophilia]. Monteil H; Jehl F Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):805-8. PubMed ID: 3309818 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM; Ueno Y; Cunha BA Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972 [TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
20. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas. WaKabongo M; Stucki ZN; Torbert DP; Olweny J J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671 [No Abstract] [Full Text] [Related] [Next] [New Search]